Recombinant bispecific single chain antibody fragments induce Fcγ-receptor-mediated elimination of CD30+ lymphoma cells

Cancer Letters

Volumn 282, Issue 2, 2009, Pages 187-194

  Ranft, Katharina ^a   Thepen, Theo ^a   Fischer, Rainer ^a,b   Barth, Stefan ^a,b   Stöcker, Michael ^b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bispecific scFv; BSM; Fc receptor I; Hodgkin's lymphoma; Phagocytosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD30 ANTIGEN; CD64 ANTIGEN; FC RECEPTOR; RECOMBINANT ANTIBODY; RECOMBINANT SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; EMBRYO; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD30; CELL LINE; CLONING, MOLECULAR; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PHAGOCYTOSIS; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 67649990018     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.011     Document Type: Article

References (56)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Ng A.K., and Mauch P.M. Hodgkin Disease. Encyclopedia of Life Sciences (2001), John Wiley & Sons, Ltd., Chichester pp. 1-7
3. Hoppe R.T. The John Ultmann lecture the role of radiation therapy in the treatment of Hodgkin's disease: past, present, and future. Eur. J. Haematol. 75 (2005) 14-20
4. Schnell R., Borchmann P., Schulz H., and Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann. Oncol. 13 (2002) 57-66
5. Borchmann P., Schnell R., and Engert A. Immunotherapy of Hodgkin's lymphoma. Eur. J. Haematol. Suppl. (2005) 159-165
6. Yujian Z., Laiman X., Raffit H., and Ira P. Immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc. Natl. Acad. Sci. 104 (2007) 17099-17104
7. Yan L., Hsu K., and Beckman R.A. Antibody-based therapy for solid tumors. Cancer J. 14 (2008) 178-183
8. Fietz T., and Thiel E. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. Recent Results Cancer Res. 176 (2007) 153-163
9. Falini B., Pileri S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M.F., and Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85 (1995) 1-14
10. Gruss H.J., Boiani N., Williams D.E., Armitage R.J., Smith C.A., and Goodwin R.G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83 (1994) 2045-2056
11. Schnell R., Dietlein M., Staak J.O., Borchmann P., Schomaecker K., Fischer T., Eschner W., Hansen H., Morschhauser F., Schicha H., Diehl V., Raubitschek A., and Engert A. Treatment of refractory Hodgkin's lymphoma Patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J. Clin. Oncol. 23 (2005) 4669-4678
12. Oflazoglu E., Kissler K.M., Sievers E.L., Grewal I.S., and Gerber H.P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Brit. J. Haematol. 142 (2008) 69-73
13. Matthey B., Engert A., and Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review). Int. J. Mol. Med. 6 (2000) 509-514
14. Barth S., Schnell R., Diehl V., and Engert A. Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann. Oncol. 7 Suppl. 4 (1996) 135-141
15. Segal D.M., Weiner G.J., and Weiner L.M. Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11 (1999) 558-562
16. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmüller G., Reinhardt C., Baeuerle P.A., and Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008) 974-977
17. Maletz K., Kufer P., Mack M., Raum T., Pantel K., Riethmüller G., and Gruber R. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int. J. Cancer 93 (2001) 409-416
18. Reusch U., Sundaram M., Davol P.A., Olson S.D., Davis J.B., Demel K., Nissim J., Rathore R., Liu P.Y., and Lum L.G. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin. Cancer Res. 12 (2006) 183-190
19. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
20. Van Vugt M.J., Van den Herik-Oudijk I.E., and Van de Winkel J.G. FcgammaRIa-gamma-chain complexes trigger antibody-dependent cell-mediated cytotoxicity (ADCC) in CD5+ B cell/macrophage IIA1.6 cells. Clin. Exp. Immunol. 113 (1998) 415-422
21. Moore T., Ekworomadu C., Eko F., MacMillan L., Ramey K., Ananaba G., Patrickson J., Nagappan P., Lyn D., Black C., and Igietseme J. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis. 188 (2003) 617-624
22. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol. Immunother. 45 (1997) 210-215
23. Hetzel C., Bachran C., Fischer R., Fuchs H., Barth S., and Stöcker M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J. Immunother. 31 (2008) 370-376
24. Graziano R.F., Tempest P.R., White P., Keler T., Deo Y., Ghebremariam H., Coleman K., Pfefferkorn L.C., Fanger M.W., and Guyre P.M. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J. Immunol. 155 (1995) 4996-5002
25. Guyre P.M., Graziano R.F., Vance B.A., Morganelli P.M., and Fanger M.W. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J. Immunol. 143 (1989) 1650-1655
26. Honeychurch J., Tutt A.L., Valerius T., Heijnen I.A.F.M., Van de Winkel J.G.J., and Glennie M.J. Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 96 (2000) 3544-3552
27. Ely P., Wallace P.K., Givan A.L., Graziano R.F., Guyre P.M., and Fanger M.W. Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 87 (1996) 3813-3821
28. Bevaart L., Goldstein J., Vitale L., Russoniello C., Treml J., Zhang J., Graziano R.F., Leusen J.H.W., Winkel J.G.J., and Keler T. Direct targeting of genetically modified tumour cells to Fcgamma RI triggers potent tumour cytotoxicity. Brit. J. Haematol. 132 (2006) 317-325
29. Sundarapandiyan K., Keler T., Behnke D., Engert A., Barth S., Matthey B., Deo Y.M., and Graziano R.F. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J. Immunol. Methods 248 (2001) 113-123
30. Borchmann P., Schnell R., Fuss I., Manzke O., Davis T., Lewis L.D., Behnke D., Wickenhauser C., Schiller P., Diehl V., and Engert A. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100 (2002) 3101-3107
31. Klimka A., Barth S., Matthey B., Roovers R.C., Lemke H., Hansen H., Arends J.W., Diehl V., Hoogenboom H.R., and Engert A. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Brit. J. Cancer 80 (1999) 1214-1222
32. Tur M.K., Huhn M., Thepen T., Stöcker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern R., and Barth S. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 63 (2003) 8414-8419
33. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 (1977) 59-72
34. Diehl V., Kirchner H., MC S., Stein H., Gerdes J., and Boie C. Hodgkin's disease: establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. Oncol. 101 (1981) 111-124
35. Ziegler-Heitbrock H., Thiel E., Fütterer A., Herzog V., Wirtz A., and Riethmüller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41 (1988) 456-461
36. Drocourt D., Calmels T., Reynes J.P., Baron M., and Tiraby G. Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucleic Acids Res. 18 (1990) 4009
37. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning (1998), Cold Spring Harbor Laboratory Press
38. Stöcker M., Tur M.K., Sasse S., Krussmann A., Barth S., and Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expres. Purif. 28 (2003) 211-219
39. Stöcker M., Pardo A., Hetzel C., Reutelingsperger C., Fischer R., and Barth S. Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expres. Purif. 58 (2008) 325-331
40. Stöcker M., Tur M.K., Sasse S., Krüßmann A., Barth S., and Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expres. Purif. 28 (2003) 211-219
41. Stöcker M., Pardo A., Hetzel C., Reutelingsperger C., Fischer R., and Barth S. Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expres. Purif. 58 (2008) 325-331
42. Erbe D.V., Collins J.E., Shen L., Graziano R.F., and Fanger M.W. The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells. Mol. Immunol. 27 (1990) 57-67
43. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75 (2004) 163-189
44. Delles A.M., Rittenhouse-Olson K., Morgan J., and Oseroff A.R. A simple method for the purification of human peripheral blood antigen presenting cells (dendritic cells, monocytes/macrophages, and B lymphocytes). Immunol. Invest. 31 (2002) 233-245
45. Neri S., Mariani E., Meneghetti A., Cattini L., and Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn. Lab. Immunol. 8 (2001) 1131-1135
46. Keler T., Wallace P.K., Vitale L.A., Russoniello C., Sundarapandiyan K., Graziano R.F., and Deo Y.M. Differential effect of cytokine treatment on Fcalpha receptor I- and Fcgamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J. Immunol. 164 (2000) 5746-5752
47. Kufer P., Mack M., Gruber R., Lutterbuse R., Zettl F., and Riethmüller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol. Immunother. 45 (1997) 193-197
48. Gilliland L.K., Norris N.A., Marquardt H., Tsu T.T., Hayden M.S., Neubauer M.G., Yelton D.E., Mittler R.S., and Ledbetter J.A. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47 (1996) 1-20
49. Löffler A., Kufer P., Lutterbuse R., Zettl F., Daniel P.T., Schwenkenbecher J.M., Riethmuller G., Dorken B., and Bargou R.C. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95 (2000) 2098-2103
50. Ducusin R.J., Sarashina T., Uzuka Y., Tanabe S., and Ohtani M. Phagocytic response of bovine polymorphonuclear leukocytes to different incubation conditions and following exposure to some effectors of phagocytosis and different anticoagulants in vitro. Can. J. Vet. Res. 61 (2001) 38-44
51. Li W., and Chung S.C. Flow cytometric evaluation of leukocyte function in rat whole blood. In Vitro Cell. Dev. Biol. Anim. 39 (2003) 413-419
52. Chang Y.-C., Hsu T.-L., Lin H.-H., Chio C.-C., Chiu A.W., Chen N.-J., Lin C.-H., and Hsieh S.-L. Modulation of macrophage differentiation and activation by decoy receptor 3. J. Leukocyte Biol. 75 (2004) 486-494
53. van Grevenynghe J., Rion S., Le Ferrec E., Le Vee M., Amiot L., Fauchet R., and Fardel O. Polycyclic aromatic hydrocarbons inhibit differentiation of human monocytes into macrophages. J. Immunol. 170 (2003) 2374-2381
54. Guyre C.A., Keler T., Swink S.L., Vitale L.A., Graziano R.F., and Fanger M.W. Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG. J. Immunol. 167 (2001) 6303-6311
55. Huang M.T., and Gorman C.M. Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. 18 (1990) 937-947
56. Rees S., Coote J., Stables J., Goodson S., Harris S., and Lee M.G. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20 (1996) 102-104 106, 108-110